DGAP-News

Evotec achieves further milestones in TargetAD collaboration with Janssen - Seite 2

gaps develop in the temporal lobe and hippocampus, which are responsible
for storing and retrieving new information. Beside degeneration of neurons,
typical pathological hallmarks for AD are beta amyloid plaques and
neurofibrillary tangles composed by Tau protein in the brain. The cause and
progression of AD however are still not completely understood. Like other
chronic conditions, scientists believe that AD doesn't have one predominant
cause, but is rather a complex result of various factors. At the moment,
there is no cure available for AD and most other causes for dementia.
Current treatments only tackle the symptoms of the disease.
According to Alzheimer's Disease International, there were 44 million
people diagnosed with dementia in 2013 worldwide. It is estimated that this
number is going to increase to more than 135 million people in 2050.
Approximately 7.7 million new cases of dementia are diagnosed each year.
Concerning the dementia market volume, $ 604 bn were spent on the treatment
of dementia in 2010. All in all, these costs equal about 1% of the world's
GDP (average of GDP from countries worldwide).


ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies. We operate worldwide providing
the highest quality stand-alone and integrated drug discovery solutions,
covering all activities from target-to-clinic. The Company has established
a unique position by assembling top-class scientific experts and
integrating state-of-the-art technologies as well as substantial experience
and expertise in key therapeutic areas including neuroscience, pain,
metabolic diseases as well as oncology, inflammation and infectious
diseases. Evotec has long-term discovery alliances with partners including
Bayer, Boehringer Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals,
MedImmune/AstraZeneca, Roche and UCB. In addition, the Company has existing
development partnerships and product candidates both in clinical and
pre-clinical development. These include partnerships with Boehringer
Ingelheim and MedImmune in the field of diabetes, with Janssen
Pharmaceuticals in the field of depression and with Roche in the field of
Alzheimer's disease. For additional information please go to
www.evotec.com.

Contact Evotec AG:
Gabriele Hansen, VP Corporate Communications & Investor Relations, Phone:
+49.(0)40.56081-255, [e-mail]